Patent Application
20110152320
The present invention relates to 1,5-diphenylpyrrole-3-carboxamide derivatives, to their preparation and to their therapeutic application.
Derivatives of 1,5-diphenylpyrrole-3-carboxamide, which are active as anti-obesity agents, have been described in patent application WO 2003/027 069. Derivatives of 1,5-diphenylpyrrole-3-carboxamide, exhibiting affinity for the CB1 cannabinoid receptors, have been described in patent applications WO 2004/058 249 and WO 2005/080 328. Application WO 2006/024 777 claims 4,5-diphenylpyrrole-2-carboxamides exhibiting affinity for the CB1 cannabinoid receptors.
Novel 1,5-diphenylpyrrole-3-carboxamide derivatives carrying a particular substituent at the 2-position of the pyrrole have now been found which possess antagonist properties for the CB1 cannabinoid receptors. In particular, these novel derivatives have antagonist properties for the peripheral CB1 receptors and exhibit low penetration at the level of the brain.
The subject of the present invention is compounds corresponding to the formula:
in which:
The compounds of formula (I) may contain one or more asymmetric carbon atoms. They can therefore exist in the form of enantiomers or diastereoisomers. These enantiomers, diastereoisomers and mixtures thereof, including the racemic mixtures, form part of the invention.
The compounds of formula (I) may exist in the form of bases (that is to say as they are in their free forms), of addition salts with acids or of addition salts with bases. These salts are advantageously prepared with pharmaceutically acceptable salts but the salts of other acids which are useful, for example, for the purification or isolation of the compounds of formula (I) also form part of the invention.
The expression (C1-C3)alkyl, (C1-C4)alkyl or (C1-C6)alkyl group is understood to mean respectively a linear or branched alkyl radical of one to three carbon atoms, of one to four carbon atoms or of one to six carbon atoms, such as the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, n-hexyl or isohexyl radical. The methyl group is preferred for a (C1-C3)alkyl, for a (C1-C4)alkyl and for a (C1-C6)alkyl.
The expression (C1-C3)alkylene or (C1-C6)alkylene group is understood to mean respectively a linear bivalent carbon radical of one to three carbon atoms or of one to six carbon atoms such as —(CH2)—, —(CH2)2—, —(CH2)3—, —(CH2)4—, —(CH2)5— and —(CH2)6.
The expression (C1-C4)alkoxyl is understood to mean an oxygen atom attached to a linear or branched carbon radical of one to four carbon atoms such as methoxyl, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy or tert-butoxy radical. The methoxyl group is preferred.
The expression halogen atom is understood to mean a fluorine, chlorine, bromine or iodine atom, the fluorine, chlorine or bromine atoms being preferred. The expression (C3-C7)cycloalkyl group is understood to mean a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl radical.
The expression amino-cycloalkyl group is understood to mean, for the cycloalkyl part, a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl carbon radical.
The expression 4- to 7-membered saturated or unsaturated heterocyclic radical, containing or not containing a second heteroatom such as O, N or S, is understood to mean in particular radicals such as homopiperidin-1-yl, morpholin-4-yl, piperidin-1-yl, piperazin-1-yl, pyrrolidin-1-yl, azetidin-1-yl, the piperidin-1-yl and pyrrolidin-1-yl radicals being preferred.
According to a first variant of the invention, the compounds of formula (IA) are differentiated in which:
According to this first variant (IA), preference is given to the compounds in which the radical R2 represents a homopiperidin-1-yl, piperidin-1-yl, pyrrolidin-1-yl or azetidin-1-yl radical, the said radicals being substituted once or twice with a substituent each independently chosen from a fluorine atom, a (C1-C4)alkoxyl, trifluoromethyl, —OCF3, —CH2OH or —CONH2 group and/or a phenyl group, the said phenyl group being unsubstituted or substituted once or twice with a substituent each independently chosen from a halogen atom, a —CF3 group, a methoxyl group and/or a trifluoromethoxyl group.
According to this first variant (IA), preference is given to the compounds in which R1 represents a hydrogen atom.
According to a second variant of the invention, the compounds of formula (IB) are differentiated in which R1 and R2 together with the nitrogen atom to which they are attached constitute:
According to this second variant, preference is given to the compounds in which:
According to this second variant (IB), preference is given in particular to the compounds in which R1 and R2 together with the nitrogen atom to which they are attached constitute a piperidin-1-yl radical which is substituted once or twice with a substituent. The substituent(s) are each independently chosen from those indicated above for this second variant (IB).
For the 2 variants according to the invention, preference is given to the compounds in which:
In particular, for R9, preference is given to an —OR12, —NR12R13, —CONR12R13,
—NR15COR12 or —NR18SO2R14 group. As regards the −OR12 and —NR12R13 groups, preference is given more particularly to R12 and R13 which are different from hydrogen.
According to the present invention, preference is given to the compounds in which R10 represents a hydrogen.
Among the compounds according to the invention, mention may be made in particular of the compounds below, as they are and the salts thereof:
Among the compounds listed above, preference is given to:
and their salts.
The subject of the present invention is also a method for preparing the compounds according to the invention.
This method is characterized in that the acid of formula (II) or a functional derivative of this acid of formula
in which R3, R4, R5, R6, R7, R9, R10 and A-R9 are as defined for (I), is treated with an amine of formula HNR1R2 in which R1 and R2 are as defined for (I).
Optionally, the compound thus obtained is converted to one of its salts.
As a functional derivative of the acid (II), use may be made of the acid chloride, the anhydride, a mixed anhydride, a C1-C4 alkyl ester in which the alkyl is straight or branched, a benzyl ester, an activated ester, for example the p-nitrophenyl ester, or the free acid opportunely activated, for example, with N,N-dicyclohexylcarbodiimide or with benzotriazol-1-yloxotris(dimethylamino)phosphonium hexafluorophosphate (BOP) or benzotriazol-1-yloxotris(pyrrolidino)phosphonium hexafluorophosphate (PyBOP) or N—[N-(dimethylamino)-1-1,2,3-triazolo[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium N-oxide]hexafluorophosphate (HBTU). These functional derivatives of the acid (II) correspond to the compounds (Ilbis).
Thus, in the method according to the invention, it is possible to cause the acid chloride, obtained by the reaction of thionyl chloride with the acid of formula (II), to react with an amine HNR1R2, in an inert solvent, such as a chlorinated solvent (dichloromethane, dichloroethane, chloroform for example), an ether (tetrahydrofuran, dioxane for example), or an amide (N,N-dimethylformamide for example) under an inert atmosphere, at a temperature between 0° C. and room temperature, in the presence of a tertiary amine such as triethylamine, N-methylmorpholine or pyridine.
One variant consists in preparing the mixed anhydride of the acid of formula (II) by reacting ethyl chloroformate with the acid of formula (II), in the presence of a base such as triethylamine, and to cause it to react with an amine HNR1R2, in a solvent such as dichloromethane, under an inert atmosphere, at room temperature, in the presence of a base such as triethylamine.
Alternatively, the compounds of formulae (I) may be prepared according to the procedure of scheme 1 below.
According to scheme 1, the acid of formula (IIa) or one of its functional derivatives in which Z represents a group which is a chemical precursor of the group A-R9 is treated with an amine of formula HNR1R2 as defined above in order to obtain an amide of formula (Ia).
Next, the group Z of the compound of formula (Ia) thus obtained is converted to a group A-R9 by a method known to a person skilled in the art in order to obtain the product of formula (I).
By way of examples, the compounds of formula (I) in which R9 corresponds to NHSO2Alk, may be synthesized from the derivatives (IIa) in which Z corresponds to A-OCH2Ph by reacting with an amine HNR1R2, followed by debenzylation as described in step (d2) of scheme 2 below, and application of the reaction sequence described in scheme 4 below.
The compounds of formula (I) obtained by the various procedures may be subsequently separated from the reaction medium and purified according to conventional methods, for example by crystallization or chromatography.
The compounds of formula (II) and their precursors may be prepared according to scheme 2 below:
Step (a2) is a regioselective alkylation of methyl acetoacetate according to the procedure described in particular in JACS 96(4) 1974, page 1082 to 1087.
Step (b2) is an alkylation of compound (III) with a bromoacetophenone, in the presence of NaH.
Step (c2) is a cyclization of the diketone (III) with a substituted aniline (Paal-Knorr reaction). This cyclization is conventionally carried out in a solvent such as toluene under reflux in the presence of para-toluenesulphonic acid, or in acetic acid. It is also possible to carry out this cyclization with better yields in the presence of catalysts such as Montmorillonite K10 and in a microwave oven, as described in Adv. Synth. Catal. 2006, 348, 2191-2196.
Step (d2) is a benzyl ether deprotection which may be carried out for example with the aid of BBr3 or BCl3 in dichloromethane.
The alcohol (VI) obtained is then saponified, preferably with LiOH, at 70° C. in a methanol-water mixture.
The acid (II) thus obtained is treated with the amine HN—R1R2 to form the product (I) of the invention.
According to the various values of the group A, it is possible to use various methods, known to a person skilled in the art, to prepare the compounds of formula (II) and the compounds of formula (I) according to the invention.
In particular, when A corresponds to —CH2—, the synthesis of the compound (III) is carried out by treating methyl 4-chloroacetoacetate with benzyl alcohol in the presence of NaH as described in scheme 3 below:
According to the various values of the R9 group, it is possible to use various methods, known to a person skilled in the art, to prepare the compounds of formula (II) and the compounds of formula (I) according to the invention.
Thus, when a compound of formula (I) is prepared in which A-R9 represents the group —(CH2)3NHSO2Alk, it is possible to carry out the procedure as according to scheme 4 below:
In this method, the alcohol (VI) is converted to a compound with a mesylate group (VIII) which is then treated with the sulphonamide H2NSO2Alk in order to obtain the alkylsulphonamide derivative (IX).
One variant consists in carrying out the procedure according to scheme 5 below by converting the compound with the mesylate group (VIII) to an amine, and then treating the latter with a compound of the AlkSO2Cl type in order to obtain the ester (IX). The conversion of the alcohol (VI) to an amine (XIV) may be carried out by various methods known to a person skilled in the art, such as for example the Mitsunobu method.
The remainder of the synthesis is carried out by saponifying the ester (IX) and by coupling the acid obtained with the appropriate amine, as described in the general scheme 2.
In the case where the group R9 represents COOH, the synthesis may be carried out according to scheme 6 below by oxidizing the compound (VI) to an acid with the aid of an oxidizing agent such as CrO3, the acid obtained being protected with a t-butyl ester group. The methyl ester of the compound (XI) is saponified in order to obtain the acid (XII), which is then coupled with the amine HNR1R2 in order to obtain the ester (XIII) which is finally deprotected to give the compound according to the invention (I).
It is also possible, where appropriate, to directly oxidize a compound of formula (I), R9 being equal to OH, with chromium VI in order to obtain the desired acid. This acid may then be treated so as to obtain the R9 groups whose definition is given in the general formula.
The amines of formula HNR1R2 are known or prepared by known methods, for example that described in J. Med. Chem.; 7; 1964; 619, 622.
The subject of the present invention is also the compounds of formula (II) and their functional derivatives (Ilbis), used for the preparation of the compounds of formula (I). Among these compounds of formula (II) and (Ilbis), those of formula (IIter) are differentiated in particular:
in which:
More particularly, the subject of the present invention is the compounds of formula:
in which
As regards the —OR12 and —NR12R13 groups in the compounds of formula (IIter), preference is given more particularly to R12 and R13 which are different from hydrogen. More particularly, preference is given to R9 which represents —OH, —NHSO2CH3, —NHSO2CF3, —O—(CH2)2—OH.
The following examples describe the preparation of some compounds in accordance with the invention. These examples are not limiting and merely illustrate the present invention. The numbers for the compounds exemplified refer to those given in the table below, which illustrates the chemical structures and the physical properties of some compounds according to the invention.
In the examples, the following abbreviations are used:
The nuclear magnetic resonance spectra are recorded at 250 MHz or at 400 MHz in DMSO-d6. For the interpretation of the spectra, the following abbreviations are used:
s: singlet, t: triplet, u.c.: unresolved complex, bm: broad multiplet, mt: multiplet, bs: broad singlet, bd: broad doublet, d: doublet, dd: doublet of doublet, dt: doublet of triplet, bt: broad triplet, 2s: 2 singlet, q: quadruplet, quin: quintuplet.
The compounds according to the invention are analyzed by LC/UV/MS (liquid chromatography/UV detection/mass spectrometry) coupling. The characteristic molecular peak (MH+, MNa+, etc.) and the retention time (tr) in minutes (min) are measured.
Conditions A (HPLC)
Use is made of a Symmetry C18 column of 2.1×50 mm, 3.5 μm.
The eluent is made up as follows:
Gradient:
Column temperature: 30° C., flow rate 0.4 ml/minute.
The UV detection is carried out at λ=210 nM and the mass detection in positive ESI chemical ionization mode.
The UV detection is carried out with a diode array detector between 210 and 400 nm and the mass detection in positive ESI mode.
Conditions B (HPLC)
Use is made of an Xterra MS C18 column of 2.1×50 mm, 3.5 μm.
The eluent is made up as follows:
Gradient:
Column temperature: 30° C., flow rate: 0.4 ml/minute.
Detection: λ=220 nm
Conditions C (HPLC):
Use is made of an Acquity BEH C18 column (50×2.1 mm; 1.7 μm)
The eluent is made up as follows:
Gradient:
Column temperature: 40° C., flow rate: 1 ml/minute.
Detection: λ=220 nm
Conditions D
Use is made of an Xterra MS C18 column of 2.1×50 mm, 3.5 μm.
The eluent is made up as follows:
solvent B: acetonitrile
Gradient:
Column temperature: ambient, flow rate: 0.4 ml/minute.
Detection: λ=220 nm
Conditions E:
Use is made of an Acquity BEH C18 column of 2.1×50 mm; 1.7 μm)
The eluent is made up as follows:
Gradient:
Column temperature: 40° C., flow rate: 1 ml/minute.
Detection: λ=220 nm
9.64 g of NaH are suspended in 300 ml of anhydrous THF. The suspension is cooled to 0° C. 20 g of methyl acetoacetate are added dropwise and the mixture is kept stirred for 45 minutes. The solution is then cooled to −20° C., and 96 ml of a 2.5 molar solution of n-BuLi in hexane are added. After stirring for 15 minutes, 51.8 g of benzyl 2-bromoethyl ether are added and the temperature is allowed to rise to 0° C. The solution is then neutralized with 200 ml of 1N HCl. The solution is diluted with 500 ml of ether, washed with H2O, dried over MgSO4, and evaporated. 50 g of an oil are obtained which, after chromatography (eluent cyclohexane/ethyl acetate), give 22.6 g of a colourless oil.
LCMS: M Na+=273, tr=8.18.
3.61 g of NaH are suspended in 500 ml of anhydrous THF. The mixture is cooled to 0° C. and 22.6 g of the compound of the preceding step 1A) diluted in 200 ml of THF are added dropwise. The mixture is kept stirred for 30 minutes and 24.1 g of 2,4-dichlorophenyl bromomethyl ketone dissolved in 100 ml of THF are added dropwise. The mixture is kept stirred for 3 hours at 0° C., and then for 17 hours at RT. The suspension is cooled to 0° C., and neutralized with 200 ml of N HCl. The mixture is extracted with ether, washed with H2O, dried over MgSO4, evaporated and chromatographed on 400 g of silica (eluent: cyclohexane/EtOAc). 25.7 g of the target compound are obtained.
LCMS: M=436(2Cl), tr=11.01.
In a round-bottomed flask provided with a Dean-Stark condenser, 25.7 g of the compound obtained in the preceding step 1B) in 400 ml of toluene are heated under reflux for 3 days with 1 g of para-toluenesulphonic acid and 8.4 g of 4-chlorophenyl amine. The solution is then diluted with EtOAc, washed with saturated NaHCO3, N HCl, dried over MgSO4 and evaporated. The oil obtained is purified by chromatography on 400 g of silica (eluent cyclohexane/EtOAc gradient) to give 23.6 g of the desired compound.
LCMS: MNa+=524.8(3Cl) tr=9.95.
23.6 g of the compound obtained above in step 1C) are introduced into 300 ml of CH2Cl2. The mixture is cooled to −5° C. and a solution of 40 g of BCl3 dimethyl sulphide in THF is added. The mixture is kept stirred for one hour, and then 70 ml of H2O are added, the mixture is allowed to separate by settling, the organic phase is washed with H2O, dried over MgSO4, concentrated under vacuum and the product obtained is purified by chromatography on silica (eluent cyclohexane/EtOAc gradient). 15.6 g of the desired compound are obtained.
0.5 g of the compound obtained in 1D) is introduced into 10 ml of CH2Cl2. 0.4 ml of DIPEA and 153 mg of DMAP are added. The mixture is cooled to −10° C. and 150 mg of mesyl chloride are added. The mixture is allowed to react for 2 hours at −10° C., washed with a solution of H2O buffered to pH=2. The organic phase is dried over MgSO4 and then evaporated. 0.59 g of the desired compound is obtained in the form of an oil.
LCMS: MH+=516.1, tr=2.06.
This step is carried out according to the information published in: Tetrahedron Letters 46 (2005) page 22159-2161.
18 mg of NaH are introduced into 10 ml of anhydrous DMF. The mixture is cooled to 0° C. and 42.7 mg of methyl sulphonamide are added and allowed to react for 15 minutes. A solution of 150 mg of the compound of the preceding step 1E) dissolved in 5 ml of anhydrous DMF is added. The mixture is allowed to return to RT and then the mixture is left for 3 hours at 60° C. The DMF is evaporated under vacuum, the residue is redissolved in CH2Cl2, washed with H2O, dried over MgSO4 and evaporated. 93 mg of the desired compound are obtained after chromatography (cyclohexane/EtOAc).
LCMS: MH+ (—OMe)=485.0, tr=1.96.
3.43 g of the product obtained in step 1F) are dissolved in 200 ml of methanol. 20 ml of water are added and the mixture is kept stirred for 17 hours at 65° C. The methanol is partially evaporated, and then the mixture is diluted with CH2Cl2 and acidified with concentrated HCl to pH=1 while cooling. The organic phase is dried over MgSO4, filtered and evaporated, and 3.24 g (97%) of a white solid are obtained.
LCMS: MH+ (—OMe)=485.1, tr=1.74.
13.28 g of NaH are introduced into 200 ml of dry THF. The mixture is cooled to about 0° C. and then 25 g of methyl ester of 4-chloro-3-oxobutyric acid are added dropwise. 17 ml of benzyl alcohol are then added dropwise. The solution takes on a red colour. The mixture is kept stirred at RT for 17 hours and the reaction mixture is poured into 120 ml of 2N HCl. The mixture is extracted with ether. The organic phase is dried over MgSO4 and evaporated. After chromatography (eluent: cyclohexane/EtOAc), 23.5 g of product are obtained.
4.13 g of NaH are introduced into 500 ml of dry THF, cooled to 0° C. 23 g of the compound obtained in step 2A) are added dropwise. The mixture is kept stirred for 30 minutes, and then 27.7 g of 2,4-dichlorophenacyl bromide are added dropwise. The mixture is allowed to react for 3 hours at 0° C., and then the temperature is raised to RT for 17 hours. 150 ml of 2N HCl are added, after cooling, followed by extraction with ether, washing with H2O, drying and evaporation. 26 g of product are obtained whose analysis by LCMS confirms the structure.
To a round-bottomed flask are added 3.8 g obtained in step 2B), 15 ml of CH2Cl2 and 4 g of Montmorillonite K10. The mixture is kept stirred under nitrogen for 72 hours. The mixture is filtered, rinsed with CH2Cl2, washed with dilute HCl, dried and the organic phase is evaporated. After chromatography, 3 g of the desired pyrrole are obtained.
8 g of the product of step 2C) in 150 ml of CH2Cl2 are dissolved in a round-bottomed flask. The mixture is cooled to 0° C. and 13 g of BCl3-dimethyl sulphide complex dissolved beforehand in 50 ml of CH2Cl2 are added dropwise. After reacting for 1 hour, the mixture is neutralized with solid NaHCO3 until the gaseous release ceases. The organic phase is dried, and 4.5 g of oil are obtained after chromatography whose NMR spectrum confirms the structure.
2.7 g of the compound of step 2D) are reacted with 1 g of LiOH in a mixture of dioxane and H2O 90/10 for 17 hours at 60° C. After evaporation, the mixture is redissolved in CH2Cl2, washed with a solution pH=2, and purified by chromatography. 350 mg of the desired product are obtained whose structure is confirmed by LCMS and NMR.
0.5 g of the compound obtained in step 1G) of Preparation 1, 0.7 ml of DIPEA and 350 mg of 4-phenylpiperidine-4-carboxamide acid in 10 ml of CH2Cl2 are introduced into a round-bottomed flask under nitrogen. The mixture is cooled to 0° C. 3.25 g of TBTU are added and the mixture is kept stirred for 30 minutes. The mixture is washed with saturated NaHCO3, buffer 2, and then with a saturated NaCl solution. The mixture is dried over MgSO4, filtered and evaporated.
The crude product is chromatographed on silica (eluent CH2Cl2/MeOH) to give 0.48 g of the desired compound whose structure is confirmed by LCMS and NMR.
LC/MS (B): MH+=687, tr=10. 16.
There is dissolved 0.3 g of the product obtained in step 2E) of Preparation 2 in 20 ml of CH2Cl2, with 27 ml of DIPEA. 0.16 g of [1,4]bipiperidinyl-4′-carboxamide and 0.22 g of TBTU are then added. The mixture is kept stirred for 1 hour and then diluted with 50 ml of CH2Cl2, washed with a buffer solution pH=2, a saturated NaHCO3 solution, the organic phase is dried and evaporated. 350 mg of the solid compound are obtained after chromatography whose structure is confirmed by LCMS and NMR.
In a round-bottomed flask under nitrogen, 5 g of the compound obtained in step 1D) of Preparation 1 are dissolved in 180 ml of water and 20 ml of methanol. 5 g of LiOH are added and the mixture is heated at 60° C. for 17 hours. The solvent is evaporated under vacuum and the residue obtained is redissolved in 100 ml of CH2Cl2 and 50 ml of water. After acidification with HCl to pH=1, drying of the organic phase with MgSO4, filtration and then evaporation, 4.67 g of an acid compound are obtained.
Into a round-bottomed flask under nitrogen are introduced 300 mg of the acid obtained in step 3a) in 30 ml of DMF, 246 mg of 4-(4-chlorophenyl)piperidine-4-carboxamide (prepared according to the procedure described in patent application US 2005/0070549, in particular in Example 460, paragraphs 1394 to 1397), 0.62 ml of DIPEA and 250 mg of TBTU.
The mixture is kept stirred for 17 hours at RT. The mixture is evaporated, taken up in CH2Cl2, washed with N HCl, dried over MgSO4, filtered and evaporated. The crude product is chromatographed on silica (eluent CH2Cl2/MeOH) to give 0.32 g of the desired compound whose structure is confirmed by LCMS and NMR.
Table 1 shows the chemical structures of some compounds according to the invention and their physical properties (analysis by LC/UV/MS coupling: liquid chromatography/UV detection/mass spectrometry). In this table, Me means methyl. The compounds listed are prepared according to the methods of preparation described above and in particular by following procedures similar to those described in Examples 1 to 3.
The analyses carried out by NMR for some compounds are given below:
1H NMR: DMSO-d6 (250 MHz): δ (ppm): 1.20-1.99: u.c.: 10H, 2.52-3.02: u.c.: 8H, 3.17: t: 2H, 3.55: bd: 2H, 4.41: bd: 2H, 6.38: s: 1H, 7.22: d: 2H, 7.27-7.31: u.c.: 2H, 7.43: d: 2H, 7.53: d: 1H, 8.18: bs: 2H, 10.23: t: 1H.
1H NMR: DMSO-d6 (400 MHz): δ (ppm): 1.30-1.58: u.c.: 8H, 1.73: mt: 2H, 1.88: bd: 2H, 2.45: bt: 4H, 2.62: t: 2H, 2.73: q: 2H, 2.78: s: 3H, 3.35: bs: 2H; 3.86: bm: 2H, 6.37: s: 1H, 6.93: d: 1H, 6.98-7.11: 2s: 2H, 7.20-7.37: u.c.: 4H, 7.45: d: 2H, 7.58: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm): 1.27-1.97: u.c.: 12H, 2.45: bs: 4H, 2.65: t: 2H, 2.92: t: 2H, 3.38: mt: 2H, 3.85: bd: 2H, 6.38: s: 1H, 6.96-7.13: 2s: 2H, 7.17-7.39: u.c.: 4H, 7.46: d: 2H, 7.58: d: 1H, 8.18: bs: 2H, 10.23: t: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm): 1.31: quin: 2H, 1.79: mt: 2H, 2.52: mt: 2H, 2.62: t: 2H, 3.15: q: 2H, 3.23: bs: 2H, 4.10: bd: 2H, 4.44: t: 1H, 6.38: s: 1H, 7.07: s: 1H, 7.17-7.52: u.c.: 12H, 7.58: d: 1H.
1H NMR: DMSO-d6 (400 MHz): δ (ppm): 1.63: quin: 2H, 1.74-2.06: u.c.: 6H, 2.53: mt: 2H, 2.70: t: 2H, 2.90: bs: 6H, 3.38: bt: 2H, 4.05: dt: 2H, 6.41: s: 1H, 6.85: bs: 2H, 7.18-7.58: u.c.: 12H.
1H NMR: DMSO-d6 (400 MHz): δ (ppm): 1.41: quin: 2H, 1.81: mt: 2H, 2.53: u.c.: 2H, 2.62: t: 2H, 2.72: q: 2H, 2.74: s: 3H, 3.24: bs: 2H, 4.10: bs: 2H, 6.40: s: 1H, 6.91: t: 1H, 7.07: s: 1H, 7.18-7.60: u.c.: 13H.
1H NMR: DMSO-d6 (400 MHz): δ (ppm): 1.30-1.99: u.c.: 10H, 2.53-2.71: u.c.: 4H, 2.74-3.01: mt: 4H, 3.10-3.26: mt: 4H, 3.38: t: 2H, 3.57: bd: 2H, 4.38: bd: 2H, 6.39: s: 1H, 7.05: bs: 2H, 7.17-7.38: mt: 4H, 7.45: d: 2H, 7.56: s: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm): 1.60: mt: 6H, 1.64-1.97: u.c.: 4H, 2.46: bs: 4H, 3.35: t: 2H, 3.85: d: 2H, 4.31: d: 2H, 4.92: t: 1H, 6.42: s: 1H, 7.08: d: 2H, 7.21-7.51: mt: 6H, 7.60: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm): 1.05-1.30: u.c.: 4H, 1.77: t: 2H, 2.37-2.54: u.c.: 2H, 2.54-2.67: u.c.: 2H, 3.06-3.32: u.c.: 4H, 3.90-4.18: u.c.: 2H, 4.22: t: 1H, 6.38: s: 1H, 7.12: s: 1H, 7.19-7.34: u.c.: 5H, 7.37-7.51: u.c.: 6H, 7.58: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm): 1.02-1.28: u.c.: 4H, 1.78: t: 2H, 2.41-2.55: u.c.: 2H, 2.61: t: 2H, 3.14: q: 2H, 3.17-3.33: u.c.: 2H, 4.01-4.16: u.c.: 2H, 4.21: t: 1H, 6.38: s: 1H, 7.08: s: 1H, 7.16-7.54: u.c.: 12H, 7.58: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm): 1.60: d: 2H, 1.82: t: 2H, 2.27-2.48: u.c.: 3H, 2.52-2.66: u.c.: 2H, 2.74: t: 2H, 3.20-3.33: u.c.: 2H, 3.34-3.56: u.c.: 2H, 3.76-3.95: u.c.: 2H, 4.76: t: 1H, 6.35: s: 1H, 7.11: s: 1H, 7.19-7.37: u.c.: 5H, 7.40-7.53: u.c.: 2H, 7.58: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm): 1.66-2.06: u.c.: 8H, 2.54-2.67: u.c.: 4H, 2.75: t: 2H, 3.21-3.35: u.c.: 2H, 3.37-3.50: u.c.: 2H, 3.73-3.95: u.c.: 2H, 4.76: t: 1H, 6.38: s: 1H, 7.16: s: 2H, 7.22-7.39: u.c.: 4H, 7.47: d: 2H, 7.58: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm): 1.66-1.82: u.c.: 2H, 1.84-1.99: u.c.: 2H, 2.13-2.31: u.c.: 2H, 2.74: t: 2H, 2.85: t: 2H, 3.08: t: 2H, 3.24-3.34: u.c.: 2H, 3.47-3.61: u.c.: 2H, 3.61-3.72: u.c.: 2H, 4.75: t: 1H, 6.38: s: 1H, 7.21: s: 1H, 7.26: dd: 4H, 7.33: dd: 1H, 7.46: d: 2H, 7.58: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm): 1.20-1.38: u.c.: 4H, 1.63-1.98: u.c.: 4H, 2.37-2.48: u.c.: 4H, 2.73: t: 2H, 3.20-3.33: u.c.: 2H, 3.32-3.51: u.c.: 2H, 3.73-3.93: u.c.: 2H, 4.76: t: 1H, 6.38: s: 1H, 7.07: d: 2H, 7.21-7.37: u.c.: 4H, 7.47: d: 2H, 7.58: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm): 0.85: s: 6H, 1.25-1.34: u.c.: 4H, 1.35-1.50: u.c.: 2H, 1.62-2.04: u.c.: 4H, 2.36-2.48: u.c.: 4H, 2.56-2.67: u.c.: 2H, 2.68-2.78: u.c.: 2H, 2.77: s: 3H, 3.31-3.50: u.c.: 2H, 3.72-3.95: u.c.: 2H, 6.38: s: 1H, 6.94: t: 1H, 7.02-7.15: u.c.: 2H, 7.25: d: 2H, 7.29-7.34: u.c.: 2H, 7.46: d: 2H, 7.58: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm): 0.85: s: 6H, 1.18-1.52: u.c.: 6H, 1.65-2.09: u.c.: 4H, 2.37-2.47: u.c.: 4H, 2.56-2.67: u.c.: 2H, 3.15: q: 2H, 3.33-3.46: u.c.: 2H, 3.77-3.93: u.c.: 2H, 4.48: t: 1H, 6.36: s: 1H, 7.02-7.16: u.c.: 2H, 7.19-7.34: u.c.: 4H, 7.46: d: 2H, 7.58: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm): 1.29-1.50: u.c.: 2H, 1.65-1.90: u.c.: 2H, 2.37-2.51: u.c.: 2H, 2.66-2.81: u.c.: 5H, 3.05-3.28: u.c.: 2H, 3.86-4.30: u.c.: 2H, 6.40: s: 1H, 6.92: t: 1H, 7.10-7.20: u.c.: 1H, 7.21-7.37: u.c.: 6H, 7.37-7.55: u.c.: 7H, 7.59: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm): 1.23-1.40: u.c.: 2H, 1.68-1.87: u.c.: 2H, 2.37-2.50: u.c.: 2H, 2.55-2.68: u.c.: 2H, 3.14: q: 2H, 3.17-3.31: u.c.: 2H, 3.93-4.25: u.c.: 2H, 4.46: t: 1H, 6.39: s: 1H, 7.16: s: 1H, 7.20-7.34: u.c.: 5H, 7.42: s, 6H, 7.59: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm): 1.25-1.43: u.c.: 2H, 1.65-2.08: u.c.: 8H, 2.53-2.72: u.c.: 6H, 3.15: q: 2H, 3.36-3.57: u.c.: 2H, 3.70-3.91: u.c.: 2H, 4.49: t: 1H, 6.37: s: 1H, 7.17: s: 2H, 7.24: d: 2H, 7.30: s: 1H, 7.32: d: 1H, 7.46: d: 2H, 7.58: d: 1H.
1H NMR: DMSO-d6 (400 MHz): δ (ppm): 1.33-1.49: u.c.: 2H, 1.69-1.84: u.c.: 2H, 1.86-2.00: u.c.: 2H, 2.14-2.31: u.c.: 2H, 2.58-2.66: u.c.: 2H, 2.73: q: 2H, 2.78: s: 3H, 2.85: t: 2H, 3.08: t: 2H, 3.48-3.60: u.c.: 2H, 3.61-3.76: u.c.: 2H, 6.39: s: 1H, 6.93: t: 1H, 7.20: s: 1H, 7.22-7.36: u.c.: 5H, 7.46: d: 2H, 7.58: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm): 1.31-1.55: u.c.: 2H, 1.66-2.09: u.c.: 8H, 2.53-2.67: u.c.: 6H, 2.73: q: 2H, 2.77: s: 3H, 3.38-3.63: u.c.: 2H; 3.72-3.94: u.c.: 2H, 6.38: s: 1H, 6.94: t: 1H, 7.17: s: 2H, 7.25: d: 2H, 7.29-7.35: u.c.: 2H, 7.47: d: 2H, 7.59: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm): 1.22-1.40: u.c.: 2H, 1.66-1.91: u.c.: 2H, 2.42-2.56: u.c.: 2H, 2.56-2.68: u.c.: 2H, 3.14: q: 2H, 3.11-3.32: u.c.: 2H, 3.96-4.25: u.c.: 2H, 4.48: t: 1H, 6.35: s: 1H, 7.05-7.20: u.c.: 2H, 7.20-7.30: u.c.: 4H, 7.30-7.57: u.c.: 8H.
1H NMR: DMSO-d6 (400 MHz): δ (ppm): 0.00-0.16: u.c.: 2H, 0.35-0.50: u.c.: 2H, 0.80-0.96: u.c.: 1H, 1.27-1.40: u.c.: 2H, 1.52-1.65: u.c.: 2H; 1.73-1.86: u.c.: 2H, 2.09: br. s.: 1H, 2.20: d: 2H, 2.63: t: 2H, 3.17: q: 2H, 3.39-3.64: u.c.: 2H, 3.70-3.93: u.c.: 2H, 4.49: t: 1H, 6.29: s: 1H, 6.99: s: 1 H, 7.08-7.17: u.c.: 1H, 7.23: d; 2H, 7.27-7.37: u.c.: 2H, 7.39: dd: 1H, 7.44: d 2H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm) 1.24-1.40: u.c.: 2H, 1.40-1.62: u.c.: 2H, 1.64-1.84: u.c.: 2H, 2.31-2.46: u.c.: 1H, 2.61: t: 2H, 2.80-3.04: u.c.: 2 H, 3.04-3.24: u.c.: 4H, 3.37: q: 2H, 4.15-4.39: u.c.: 2H, 4.47: t: 1H, 4.63: t: 1H, 6.29: s: 1H, 7.06-7.19: u.c.: 1H, 7.24: d: 2H, 7.29-7.50: u.c.: 4H, 7.81: s: 1H
1H NMR: DMSO-d6 (250 MHz): δ (ppm) 1.06-1.40: u.c.: 4H, 1.59-2.05: u.c.: 6H, 2.06-2.36: u.c.: 2H, 2.53-2.67: u.c.: 2H, 2.74-2.95: u.c.: 2H, 3.01-3.20: u.c.: 2H, 3.46-3.77: u.c.: 4H, 6.37: s: 1H, 6.58: s: 1H, 7.12: s: 1H, 7.18-7.40: u.c.: 6H, 7.46: d: 2H, 7.57: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm) 1.63-2.00: u.c.: 4H, 2.02-2.39: u.c.: 4H, 2.66-2.80: u.c.: 2H, 2.80-2.94: u.c.: 2H, 3.10: t, 2H, 3.46-3.78: u.c.: 4 H, 6.38: s: 1H, 6.65: s: 1H, 7.14: s: 1H, 7.18-7.38: u.c.: 7H, 7.46: d: 2H, 7.58: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm) 1.70-1.90: u.c.: 2H, 2.01-2.16: u.c.: 2H, 2.45-2.58: u.c.: 2H, 2.67-2.81: u.c.: 2H, 3.34: s: 2H, 3.90-4.21: u.c.: 2H, 6.37: s: 1H, 6.63: s: 1H, 7.03-7.17: u.c.: 2H, 7.18-7.52: u.c.: 12H, 7.57: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm) 1.02-1.42: u.c.: 4H, 1.65-1.96: u.c.: 4H, 2.38-2.64: u.c.: 4H, 3.08-3.38: u.c.: 2H, 3.95-4.20: u.c.: 2H, 6.38: s: 1H, 6.56: s: 1H, 7.02-7.16: u.c.: 2H, 7.17-7.52: u.c.: 12H, 7.58: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm) 1.24-1.40: u.c.: 2H, 1.63-1.82: u.c.: 2H, 1.82-1.96: u.c.: 2H, 2.09-2.33: u.c.: 2H, 2.55-2.68: u.c.: 2H, 2.79-2.90: u.c.: 2H, 3.05: d: 1H, 3.11-3.23: u.c.: 3H, 3.45-3.75: u.c.: 4H, 4.47: t: 1H, 6.33: s: 1H, 7.08-7.29: u.c.: 5H, 7.30-7.50: u.c.: 4H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm) 1.31-1.54: u.c.: 2H, 1.69-1.93: u.c.: 4H, 2.42-2.69: u.c.: 4H, 3.07-3.28: u.c.: 2H, 4.01-4.32: u.c.: 2H, 6.35: s: 1H, 6.60: s: 1H, 7.04-7.33: u.c.: 10H, 7.35-7.54: u.c.: 5H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm)-0.01-0.12: u.c.: 2H, 0.34-0.46: u.c.: 2H, 0.75-0.96: u.c.: 1H, 1.30-1.49: u.c.: 2H, 1.49-1.67: u.c.: 2H, 1.69-1.88: u.c.: 2H, 2.07: br. s.: 1H, 2.13-2.29: u.c.: 2H, 2.56-2.67: u.c.: 2 H, 2.72: q: 2H, 2.78: s: 3H, 3.40-3.64: u.c.: 2H, 3.66-3.91: u.c.: 2H, 6.36: s: 1H; 6.94: t: 1H, 6.99-7.05: u.c.: 1H, 7.18-7.34: u.c.: 5H, 7.45: s: 2H, 7.58: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm) 0.02-0.14: u.c.: 2H, 0.33-0.45: u.c.: 2H, 0.74-0.94: u.c.: 1H, 1.22-1.38: u.c.: 2H, 1.50-1.66: u.c.: 2H, 1.69-1.86: u.c.: 2H, 2.19: d: 2H, 2.62: t: 2H, 3.16: q: 2H, 3.41-3.66: u.c.: 2H, 3.68-3.92: u.c.: 2H, 4.45: t: 1H, 6.34: s: 1H, 7.02: s: 1H, 7.17-7.36: u.c.: 5H, 7.46: d: 2H, 7.58: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm) 0.94-1.15: u.c.: 2H, 1.17-1.32: u.c.: 2H, 1.31-1.62: u.c.: 5H, 1.61-1.81: u.c.: 2H, 2.62: t: 2H, 2.73: q: 2H, 2.78: s: 3H, 2.80-3.03: u.c.: 2H, 3.38: q: 2H, 4.11-4.35: u.c.: 2H, 4.35: t: 1H, 6.33: s: 1H, 6.94: t: 1H, 7.19-7.34: u.c.: 4H, 7.46: d: 2H, 7.58: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm) 0.92-1.15: u.c.: 2H, 1.15-1.60: u.c.: 7H, 1.70: d: 2H, 2.62: t: 2H, 2.66-3.06: u.c.: 2H, 3.17: q: 2H, 3.38: q: 2H, 4.16-4.33: u.c.: 2H, 4.35: t: 1H, 4.48: t: 1H, 6.31: s: 1H, 7.24: d: 2H, 7.28-7.37: u.c.: 2H, 7.46: d: 2H, 7.58: d: 1H.
1H NMR: DMSO-d6 (400 MHz): δ (ppm) 1.33-1.49: u.c.: 2H, 1.73-1.89: u.c.: 2H, 2.46-2.54: u.c.: 2H, 2.62: t: 2H, 2.72: q: 2H, 2.75: s: 3H, 3.02-3.27: u.c.: 2H, 3.92-4.31: u.c.: 2H, 6.40: s: 1H, 6.90: t: 1H, 7.10: s: 1H, 7.17: t: 2 H, 7.21-7.38: u.c.: 5H, 7.39-7.50: u.c.: 4H, 7.58: s: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm) 1.24-1.42: u.c.: 2H, 1.66-1.86: u.c.: 2H, 2.43-2.56: u.c.: 2H, 2.62: t: 2H, 3.15: q: 2H, 3.14-3.26: u.c.: 2H, 3.99-4.21: u.c.: 2H, 4.43: t: 1H, 6.38: s: 1H, 7.10: s: 1H, 7.13-7.37: u.c.: 7H, 7.38-7.52: u.c.: 4H, 7.58: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm) 1.05-1.36: u.c.: 4H, 1.66-1.90: u.c.: 4H, 2.42-2.51: u.c.: 2H, 2.54-2.69: u.c.: 2H, 3.04-3.28: u.c.: 2H, 3.93-4.23: u.c.: 2H, 6.38: s: 1H, 6.57: s: 1H, 7.03-7.36: u.c.: 9H, 7.40-7.54: u.c.: 4H, 7.57: d: 1H.
1H NMR: DMSO-d6 (250 MHz): δ (ppm) 1.21-1.44: u.c.: 2H, 1.66-1.88: u.c.: 2H, 2.44-2.54: u.c.: 2H, 2.62: t: 2H, 3.15: q: 2H, 3.15-3.28: u.c.: 2H, 3.97-4.19: u.c.: 2H, 4.44: t: 1H, 6.34: s: 1H, 7.03-7.28: u.c.: 7H, 7.30-7.51: u.c.: 6H.
The compounds of formula (I) possess a very good affinity in vitro (IC50≦5.10−7M) for the CB1 cannabinoid receptors under the experimental conditions described by M. Rinaldi-Carmona et al. (FEBS Letters, 1994, 350, 240-244).
The antagonist nature of the compounds of formula (I) was demonstrated in vitro by the results obtained in the adenylate cyclase inhibition models as described in M. Bouaboula et al., J. Biol. Chem., 1995, 270, 13973-13980, M. Rinaldi-Carmona et al., J. Pharmacol. Exp. Ther., 1996, 278, 871-878 and M. Bouaboula et al., J. Biol. Chem., 1997, 272, 22330-22339.
The weak penetration of the compounds of formula (I) at the level of the blood-brain barrier (BBB) was evaluated in vivo by:
The interaction of the compounds of formula (I) according to the invention with the CB1 receptors present at the periphery was demonstrated in mice by measuring the blocking of the inhibitory effect induced by an agonist of the CB1 receptors (CP55940) on the gastrointestinal transit, after oral administration, as described in M. Rinaldi-Carmona et al., J. Pharmacol. Exp. Ther., 2004, 310, 905-914. A percentage reversion of the effect of CP55940 greater than 50% at 10 mg/kg indicates a significant antagonist power at the level of the CB1 receptors present at the periphery. Preferably, the percentage reversion is between 70% and 100%.
By way of examples, the following measurements were performed for compound Nos. 13, 14, 17 and 30 of Table 1.
The compounds of formula (I) are compatible with their use as a medicament.
Thus, according to another of its aspects, the subject of the invention is medicaments for human or veterinary medicine which comprise a compound of formula (I), or an addition salt thereof with a pharmaceutically acceptable acid.
Thus, the compounds according to the invention may be used in humans or in animals (in particular in mammals including, without limitation, dogs, cats, horses, bovines, sheep) in the treatment or prevention of diseases involving the CB1 cannabinoid receptors.
For example and without limitation, the compounds of formula (I) are useful as psychotropic medicaments, in particular for the treatment of psychiatric disorders including anxiety, depression, mood disorders, insomnia, delirium disorders, obsessive disorders, psychoses in general, schizophrenia, attention deficit hyperactivity disorders (ADHD) in hyperkinetic children and for the treatment of disorders linked to the use of psychotropic substances, in particular in the case of substance abuse and/or of dependence on a substance, including alcohol dependence and nicotine dependence.
The compounds of formula (I) according to the invention may be used as medicaments for the treatment of migraine, stress, diseases of psychosomatic origin, panic attacks, epilepsy, motion disorders, in particular dyskinesia or Parkinson's disease, tremors and dystonia.
The compounds of formula (I) according to the invention may also be used as medicaments in the treatment of memory disorders, cognitive disorders, in particular in the treatment of senile dementia, Alzheimer's disease, and in the treatment of attention or vigilance disorders.
Furthermore, the compounds of formula (I) may be useful as neuroprotectants, in the treatment of ischaemia, cranial traumas and the treatment of acute or chronic neurodegenerative diseases: including chorea, Huntington's chorea, Tourrette's syndrome.
The compounds of formula (I) according to the invention may be used as medicaments in the treatment of pain: neuropathic pain, acute peripheral pain, chronic pain of inflammatory origin, pain induced by an anticancer treatment.
The compounds of formula (I) according to the invention may be used as medicaments in human or veterinary medicine in the prevention and treatment of appetite disorders, craving disorders (for sugars, carbohydrates, drugs, alcohol or any appetizing substance) and/or alimentary canal disorders, in particular for the treatment of obesity or bulimia and for the treatment of type II diabetes or non-insulin-dependent diabetes and for the treatment of dyslipidemia, and of metabolic syndrome. Thus, the compounds of formula (I) according to the invention are useful in the treatment of obesity and of the risks associated with obesity, in particular the cardiovascular risks.
Furthermore, the compounds of formula (I) according to the invention may be used as medicaments in the treatment and prevention of gastrointestinal disorders, diarrhoeal disorders, ulcers, emesis, bladder and urinary disorders, liver diseases of alcohol or non-alcohol origin such as chronic cirrhosis, fibrosis, hepatic steatosis, steatohepatitis; and disorders of endocrine origin, cardiovascular disorders, hypotension, atherosclerosis, haemorrhagic shock, septic shock, asthma, chronic bronchitis, chronic obstructive pulmonary disease, Raynaud's syndrome, glaucoma, fertility disorders, premature labour, abortion, inflammatory phenomena, immune system diseases, in particular autoimmune and neuroinflammatory diseases such as rheumatoid arthritis, reactive arthritis, diseases causing demyelinization, multiple sclerosis, infectious and viral diseases such as encephalitis, stroke and as medicaments for anticancer chemotherapy, for the treatment of Guillain-Barré syndrome and for the treatment of bone diseases and of osteoporosis. Furthermore, the compounds of formula (I) according to the invention may be used for their protective effects against drug-induced cardiotoxicity.
According to the present invention, the compounds of formula (I) are most particularly useful for the preparation of medicaments useful for the prevention and treatment of psychiatric disorders, in particular schizophrenia, attention and vigilance disorders, attention deficit and hyperactivity disorders (ADHD) in hyperkinetic children; for the prevention and treatment of memory deficiencies and cognitive disorders; dependence and withdrawal from a substance, in particular alcohol dependence, nicotine dependence, withdrawal from alcohol and smoking cessation; acute or chronic neurodegenerative diseases.
More particularly, the compounds of formula (I) according to the present invention are useful in the preparation of medicaments useful in the treatment and prevention of appetite disorders, craving disorders, metabolism disorders, obesity, type II diabetes, metabolic syndrome, dyslipidemia, gastrointestinal disorders, inflammatory phenomena, diseases of the immune system, psychotic disorders, alcohol dependence, nicotine dependence.
According to one of its aspects, the present invention relates to the use of a compound of formula (I) and of its pharmaceutically acceptable salts for the treatment of disorders and diseases indicated above.
According to another of its aspects, the present invention relates to pharmaceutical compositions comprising, as active ingredient, a compound according to the invention. These pharmaceutical compositions contain an effective dose of at least one compound according to the invention, or a pharmaceutically acceptable salt of the said compound, and at least one pharmaceutically acceptable excipient.
The said excipients are chosen according to the pharmaceutical dosage form and the mode of administration desired, from the customary excipients which are known to persons skilled in the art.
Pharmaceutical compositions according to the present invention may contain, in addition to a compound of formula (I), one (or more) other active ingredient(s) useful in the treatment of the disorders and diseases indicated above.
Thus, the subject of the present invention is also pharmaceutical compositions containing a compound of formula (I) according to the present invention combined with one (or more) active ingredient(s) chosen from one of the following therapeutic classes:
The expression antagonist of the AT1 receptors for angiotensin II is understood to mean a compound such as candesartan cilexitil, eprosartan, irbesartan, losartan potassium, olmesartan medoxomil, telmisartan, valsartan, it being possible for each of these compounds themselves to be combined with a diuretic such as hydrochlorothiazide.
The expression converting enzyme inhibitor is understood to mean a compound such as alacepril, benazepril, captopril, cilazapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moexipril, perindopril, quinapril, ramipril, spirapril, temocapril, trandolapril, zofenopril, it being possible for each of these compounds themselves to be combined with a diuretic such as hydrochlorothiazide or indapamide or with a calcium antagonist such as amlodipine, diltiazem, felodipine or verapamil.
The expression calcium antagonist is understood to mean a compound such as amlodipine, aranidipine, benidipine, bepridil, cilnidipine, diltiazem, efonidipine hydrochloride ethanol, fasudil, felodipine, isradipine, lacidipine, lercanidipine hydrochloride, manidipine, mibefradil hydrochloride, nicardipine, nifedipine, nilvadipine, nimodipine, nisoldipine, nitrendipine, terodiline, verapamil.
The expression beta-blocker is understood to mean a compound such as acebutolol, alprenolol, amosulalol, arotinolol, atenolol, befunolol, betaxolol, bevantolol, bisoprolol, bopindolol, bucumolol, bufetolol, bunitrolol, butofilolol, carazolol, carteolol, carvedilol, cloranolol, epanolol, esmolol, indenolol, labetalol, landiolol, levobunolol, levomoprolol, mepindolol, metipranolol, metoprolol, nadolol, nebivolol, nifenalol, nipradilol, oxprenolol, penbutolol, pindolol, propranolol, salmeterol, sotalol, talinolol, tertatolol, tilisolol, timolol, xamoterol, xibenolol.
The expression antihyperlipemic or antihypercholesterolemic is understood to mean a compound chosen from fibrates such as alufibrate, beclobrate, bezafibrate, ciprofibrate, clinofibrate, clofibrate, etofibrate, fenofibrate; statins (HMG-CoA reductase inhibitors), such as atorvastatin, fluvastatin sodium, lovastatin, pravastatin, rosuvastatin, simvastatin, or a compound such as acipimox, aluminium nicotinate, azacosterol, cholestyramine, dextrothyroxine, meglutol, niceritrol, nicoclonate, nicotinic acid, beta-sitosterol, tiadenol.
The expression antidiabetic is understood to mean a compound belonging to one of the following classes: sulphonylureas, biguanidines, alpha glucosidase inhibitors, thiazolidinediones, metiglinides, such as acarbose, acetohexamide, carbutamide, chlorpropamide, glibenclamide, glibornuride, gliclazide, glimepiride, glipizide, gliquidone, glisoxepide, glybuzole, glymidine, metahexamide, metformin, miglitol, nateglinide, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide, troglitazone, voglibose, as well as insulin and insulin analogues.
The expression another anti-obesity agent or agent acting on metabolism disorders is understood to mean a compound such as amfepramone, benfluorex, benzphetamine, indanorex, mazindole, mefenorex, methamphetamine, D-norpseudoephedrine, sibutramine, a topiramate, a lipase inhibitor (orlistat cetilistat), a PPAR agonist (Peroxisome Proliferator Activated Receptor Agonist), a dopamine agonist, a leptin receptor agonist, a serotonin reuptake inhibitor, a beta-3 agonist, a CCK-A agonist, an NPY inhibitor, an agonist of the MC 4 (melanocortin 4) receptors, an antagonist of the MCH (Melanin Concentrating Hormone) receptors, an orexin antagonist, a phosphodiesterase inhibitor, an 11β-HSD (11-β-hydroxysteroid deshydrogenase) inhibitor, a DPP-IV (dipeptidyl peptidase IV) inhibitor, an antagonist (or inverse agonist) of histamine H3, a CNTF (Ciliary Neurotrophic Factor) derivative, an agonist of the GHS (Growth Hormone Secretagogue) receptors, a ghrelin modulator, a diacyglycerol acyltransferase (DGAT) inhibitor, a phosphodiesterase (PDE) inhibitor, a thyroid hormone agonist, an antagonist of the glucocorticoid receptors, a stearoyl-CoA-desaturase (SCD) inhibitor, a modulator of phosphate, glucose, fatty acid and dicarboxylate transporters, a 5HT2 antagonist, a 5HT6 antagonist, a bombesine agonist.
The expression opioid antagonist is understood to mean a compound such as naltrexone, naloxone ou nalmefene.
The expression agent useful in the treatment of alcoholism and withdrawal symptoms is understood to mean acamprosate, benzodiazepines, beta-blockers, clonidine, carbamazepine.
The expression agent useful for treating osteoporosis is understood to mean for example biphosphonates such as etidronate, clodronate, tiludronate, risedronate.
According to the present invention, it is also possible to combine other compounds having antihyperlipemic, antihypercholesterolemic, antidiabetic or anti-obesity properties. More particularly, it is possible to combine compounds belonging to one of the following classes:
PTP 1 B (Protein Tyrosine Phosphase-1B) inhibitors, agonists of the VPAC 2 receptors, GLK modulators, retinoid modulators, glycogen phosphorylase (HGLPa) inhibitors, glucagon antagonists, glucose-6-phosphate inhibitors, pyruvate dehydrogenase kinase (PDK) activators, modulators of RXR, FXR, LXR, inhibitors of SGLT (Sodium Dependant Glucose Transporter), CETP (Cholesteryl ester Transfer Protein) inhibitors, squalene synthetase inhibitors, squalene epoxidase inhibitors, triglyceride synthesis inhibitors, inducers of LDL (Low Density Lipoprotein) receptors, IBAT inhibitors, FBPase (fructose-1,6-biphosphatase) inhibitors, CART (Cocaine-Amphetamine-Regulated Transcript) modulators, antagonists of the orexin receptors.
According to another aspect of the invention, the compound of formula (I), one of its pharmaceutically acceptable salts and the other associated active ingredient may be administered simultaneously, separately or spread out over time.
The expression “simultaneous use” is understood to mean the administration of the compounds of the composition according to the invention contained in the same pharmaceutical dosage form.
The expression “separate use” is understood to mean the administration, at the same time, of two compounds of the composition according to the invention, each contained in a separate pharmaceutical dosage form.
The expression “use spread out over time” is understood to mean the successive administration of the first compound of the composition of the invention, contained in a pharmaceutical dosage form, followed by the second compound of the composition according to the invention, contained in a separate pharmaceutical dosage form. In this case, the time lapse between the administration of the first compound of the composition according to the invention and the administration of the second compound of the same composition according to the invention generally does not exceed 24 hours.
In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration, the active ingredient of formula (I) above, or its salt, may be administered in a unit form for administration, mixed with conventional pharmaceutical excipients, to animals and to human beings for the prophylaxis or treatment of the above disorders or diseases.
The appropriate unit forms for administration comprise the oral forms such as tablets, soft or hard gelatin capsules, powders, granules and oral solutions or suspensions, forms for sublingual, buccal, intratracheal, intraocular or intranasal administration or for administration by inhalation, forms for topical, transdermal, subcutaneous, intramuscular or intravenous administration, forms for rectal administration and implants. For topical application it is possible to use the compounds according to the invention in creams, gels, ointments or lotions.
By way of example, a unit form for administration of a compound according to the invention in tablet form may comprise the following components:
By the oral route, the dose of active ingredient administered per day may be up to 0.01 to 100 mg/kg, in single or divided doses, preferably 0.02 to 50 mg/kg.
There may be specific cases where higher or lower dosages are appropriate; such dosages do not depart from the scope of the invention. According to the customary practice, the dosage appropriate for each patient is determined by the doctor according to the mode of administration, the weight and the response of the said patient.
The present invention, according to another of its aspects, also relates to a method for treating the pathologies indicated above, which comprises the administration, to a patient, of an effective dose of a compound according to the invention, or of one of its pharmaceutically acceptable salts.
| Number | Date | Country | Kind |
|---|---|---|---|
| 0802552 | May 2008 | FR | national |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/FR2009/000535 | May 2009 | US |
| Child | 12942780 | US |
